Edition:
United States

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

15.99USD
21 Sep 2018
Change (% chg)

$-0.81 (-4.82%)
Prev Close
$16.80
Open
$16.80
Day's High
$16.80
Day's Low
$15.82
Volume
864,249
Avg. Vol
211,837
52-wk High
$17.96
52-wk Low
$4.02

Chart for

About

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare... (more)

Overall

Beta: 2.42
Market Cap(Mil.): $969.87
Shares Outstanding(Mil.): 60.65
Dividend: --
Yield (%): --

Financials

  DRNA.OQ Industry Sector
P/E (TTM): -- 108.33 32.69
EPS (TTM): -2.80 -- --
ROI: -103.20 1.50 12.72
ROE: -239.38 0.19 14.85

BRIEF-Dicerna Pharmaceuticals Files For Mixed Shelf Of Upto $250 Mln - SEC Filing

* DICERNA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: (https://bit.ly/2rQEqC9) Further company coverage:

May 17 2018

BRIEF-Dicerna Pharmaceuticals Q1 Loss Per Share $0.30

* DICERNA REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE

May 14 2018

BRIEF-Dicerna Pharma Files Prospectus Relates To Possible Resale Of Up To 24.5 Mln Shares Of Common Stock

* DICERNA PHARMACEUTICALS FILES PROSPECTUS RELATES TO POSSIBLE RESALE OF UP TO 24.5 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2Iya2Xu) Further company coverage:

May 11 2018

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Apr 20 2018

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Apr 20 2018

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Apr 20 2018

CORRECTED-Biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Apr 20 2018

BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals

* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION

Apr 20 2018

Earnings vs. Estimates